文献速递头颈部肿瘤放疗

肿瘤体积与癌症干细胞表达作为头颈部鳞状细胞癌高剂量局部区域失败预后标志物——DAHANCA 19研究

Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study.
PubMed 文献 · Radiother Oncol · 2024-02-09

该研究基于DAHANCA 19研究,分析340例接受原发放化疗联合尼莫拉唑的头颈部鳞状细胞癌患者的肿瘤体积、缺氧分类及癌症干细胞标志物CD44、SLC3A2、MET表达,以局部区域高剂量失败为终点。结果显示较大肿瘤体积、高SLC3A2、CD44>30%阳性及p16阴性肿瘤与更高HDF风险相关。p16阴性肿瘤中体积大者HDF风险最高,p16阳性口咽癌中高SLC3A2者HDF风险最高。

要点

  • 肿瘤体积>25 cm³与HDF风险升高相关(HR 3.00,95%CI 1.73-5.18)。
  • 高SLC3A2表达(HR 2.99)和CD44>30%阳性(HR 2.29)与HDF风险升高相关。
  • p16阴性肿瘤中体积大者HDF风险最高(HR 3.29),p16阳性口咽癌中高SLC3A2者HDF风险最高(HR 6.19)。

核心结论

  • 肿瘤体积、p16状态和癌症干细胞标志物是接受放化疗的头颈部鳞状细胞癌患者HDF的潜在生物标志物。
  • p16阳性口咽癌中癌症干细胞标志物表达较低可能有助于更好的肿瘤控制。

研究设计与样本

  • 研究纳入DAHANCA 19研究中接受原发放化疗联合尼莫拉唑治疗的头颈部鳞状细胞癌患者,获取肿瘤组织进行分析。
  • 对全部参数数据合格的患者(n=340)分析肿瘤体积、缺氧分类及癌症干细胞标志物CD44、SLC3A2、MET表达与HDF风险的关系。
  • 按p16阳性口咽癌与p16阴性肿瘤(口腔、p16阴性口咽、下咽和喉)进行分层分析。

主要发现

  • 较大原发和淋巴结体积(>25 cm³)与HDF风险升高相关(HR 3.00,95%CI 1.73-5.18)。
  • 高SLC3A2表达与HDF风险升高相关(HR 2.99,95%CI 1.28-6.99)。
  • CD44>30%阳性与HDF风险升高相关(HR 2.29,95%CI 1.05-5.00)。
  • p16阴性肿瘤与HDF风险升高相关(HR 2.53,95%CI 1.05-6.11)。
  • p16阴性肿瘤中较大体积与HDF风险最高相关(HR 3.29,95%CI 1.79-6.04,n=178);p16阳性口咽癌中高SLC3A2与HDF风险最高相关(HR 6.19,95%CI 1.58-24.23,n=162)。

关键数值与推荐

  • 肿瘤体积阈值>25 cm³,对应HDF的HR为3.00(95%CI 1.73-5.18)。
  • CD44阳性阈值>30%,对应HDF的HR为2.29(95%CI 1.05-5.00)。
  • p16阴性肿瘤对应HDF的HR为2.53(95%CI 1.05-6.11)。
  • p16阴性肿瘤中体积大的HDF的HR为3.29(95%CI 1.79-6.04)。
  • p16阳性口咽癌中高SLC3A2的HDF的HR为6.19(95%CI 1.58-24.23)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Reliable and accessible biomarkers for patients with Head and Neck Squamous Cell Carcinoma (HNSCC) are warranted for biologically driven radiotherapy (RT). This study aimed to investigate the prognostic value of putative cancer stem cell (CSC) markers, hypoxia, and tumor volume using loco-regional high-dose failure (HDF) as endpoint. MATERIALS AND METHODS: Tumor tissue was retrieved from patients treated with primary chemo-(C-)RT and nimorazole for HNSCC in the Danish Head and Neck Cancer Study Group (DAHANCA) 19 study. Tumor volume, hypoxic classification, and expression of CSC markers CD44, SLC3A2, and MET were analyzed. For patients with eligible data on all parameters (n = 340), the risk of HDF following primary chemo-(C-)RT were analyzed by these biomarkers as a whole and stratified for p16-positive oropharynx (p16 + OPSCC) vs p16-negative (p16-) tumors (oral cavity, p16- oropharynx, hypopharynx and larynx). RESULTS: Higher risk of HDF was seen for patients with larger primary and nodal volume (>25 cm3, Hazard Ratio (HR): 3.00 [95 % CI: 1.73-5.18]), high SLC3A2 (HR: 2.99 [1.28-6.99]), CD44 (>30 % positive, HR: 2.29 [1.05-5.00]), and p16- tumors (HR: 2.53 [1.05-6.11]). p16- tumors had a higher CSC marker expression than p16 + OPSCC. The factors associated with the highest risk of HDF were larger volume (HR: 3.29 [1.79-6.04]) for p16- tumors (n = 178) and high SLC3A2 (HR: 6.19 [1.58-24.23]) for p16 + OPSCC (n = 162). CONCLUSION: Tumor volume, p16, and CSC markers are potential biomarkers for HDF for patients with HNSCC treated with (C-)RT. Lower expression of CSC in p16 + OPSCC may contribute to better tumor control.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kristensen MH, Sørensen MK, Tramm T, et al. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study. Radiother Oncol. 2024. PMID: 38341096. doi:10.1016/j.radonc.2024.110149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。